Importantly, TCR‐engineered CD8+ T cells transduced with Δ133p53α acquire a long‐term proliferative capacity, show superior cytokine secretion and enhanced tumour‐specific killing in vitro and in a mouse tumour model (Legscha et al, 2021). The gene discussed is CD8A; the disease is neoplasm.